Palbociclib in liposarcoma: real-world multicenter data from the Turkish Oncology Group (TOG)

Abstract

BackgroundWell-differentiated (WDLPS) and dedifferentiated liposarcomas (DDLPS) are subtypes with distinct behaviors, often driven by CDK4 amplification. While CDK4/6 inhibitors such as palbociclib show promise in trials, real-world data are scarce.MethodsWe retrospectively analyzed 21 patients with advanced WDLPS or DDLPS treated with palbociclib monotherapy at 16 Turkish Oncology Group centers (2019-2022). Outcomes included progression-free survival (PFS), overall survival (OS), response, and safety.ResultsMedian age was 51 years; 38.1% had WDLPS and 61.9% DDLPS. Median PFS was 5.3 months and OS 9.1 months. The objective response rate was 0%, but disease control was achieved in 57.1%. WDLPS and earlier-line use were associated with numerically longer OS. Adverse events occurred in 71.4%, most often anemia (52.4%) and neutropenia (33.3%).ConclusionPalbociclib showed modest activity with disease stabilization in some patients, highlighting the need for biomarker-driven and combination strategies.